✦ LIBER ✦

Characterization of a human bladder cancer cell line selected for resistance to mitomycin C

✍ Scribed by Bing H. Xu; Vicram Gupta; Shivendra V. Singh

Publisher: John Wiley and Sons
Year: 1994
Tongue: French
Weight: 791 KB
Volume: 58
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.2910580512

No coin nor oath required. For personal study only.

✦ Synopsis

This study describes characteristics of a human bladder cancer cell line J82/MMC that is 6-fold more resistant to mitomycin C (MMC) than the parental cells. The J82/MMC subline was isolated by repeated continuous exposures of the J82/WT cells to increasing concentrations of MMC. The J82/MMC cell line showed (1) collateral sensitivity to taxol, 5-FU and topoisomerase II inhibitors; and (2) cross-resistance to cisplatin, melphalan and MMC analogues BMY 25282 and BMY 25067. Levels of two key MMC activation enzymes, NADPH cytochrome P450 reductase and DT-diaphorase, were significantly lower in J82/MMC cells compared with J82/WT, suggesting that lower sensitivity of J82/MMC cells to MMC may result from deficient drug activation. Further support is indicated by: 1) reduction in the differential in toxicity between the 2 cell lines by BMY 25282; and 2) a higher effect of DT-diaphorase inhibitor dicumarol on the wild-type cells compared with J82/MMC. Although glutathione (GSH) levels did not differ in these cells, a small but significant increase in GSH transferase (GST) activity was noticed in J82/MMC cells. GST inhibitor ethacrynic acid significantly enhanced MMC cytotoxicity in the J82/MMC cell line. A small but significant increase in the level of anti-oxidative enzyme catalase, but not GSH peroxidase, was also observed in J82/MMC cell line compared with J82/WT. Thus, the possibility that relatively lower sensitivity of J82/MMC cells to MMC may result from reduced oxygen radical generation cannot be ruled out. MMC-induced DNA interstrand cross-linking was markedly lower in the J82/MMC cell line compared with J82/WT. Our results suggest that the MMC resistance in the J82/MMC cell line may be multifactorial.

📜 SIMILAR VOLUMES

Biochemical characterization of a mitomy

Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line

✍ Shivendra V. Singh; Domenic Scalamogna; Hong Xia; Stacy O'Toole; Deodutta Roy; E 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 765 KB

This study describes characteristics of a mitomycin C (MMC)resistant human bladder cancer cell line, )82/MMC-2, which was established by repeated in vitro exposures of a 6-fold MMC-resistant variant (J82lMMC) to 18 nM MMC. A 9.6-fold higher concentration of MMC was required to kill 50% of the )82/MM

Mechanism of cross-resistance to cisplat

Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line

✍ Shivendra V. Singh; Bing H. Xu; Jitesh P. Jani; Erling O. Emerson; Mary G. Backe 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 730 KB

This study was undertaken to elucidate the mechanism@) of cross-resistance to cisplatin (CDDP) in a mitomycin C (MMC)resistant human bladder cancer cell line, J82/MMC. The J82/ MMC cell line displayed 2-to 3-fold cross-resistance to CDDP and carboplatin when compared to the parental )82/WT cells. Dr

Mechanism of increased sensitivity to et

Mechanism of increased sensitivity to etoposide in a mitomycin C-resisitant human bladder cancer cell line

✍ Hong Xia; Richard J. Bleicher; Vicram Gupta; Howard A. Zaren; Shivendra V. Singh 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 257 KB 👁 1 views

The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is G9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated. Colony formation assays, following 1 hr drug exposure, revealed that about a 2.2-

Therapeutic differentiation in a human r

Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D

✍ Jose Prados; Consolación Melguizo; Juan Antonio Marchal; Celia Vélez; Luis Alvar 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 258 KB 👁 2 views

Classical cytotoxic treatment of rhabdomyosarcoma (RMS) is accompanied often by significant morbidity and poor response. The use of cytotoxic agents may induce a multidrug resistance phenotype, which plays an important role in the sensitivity of tumoral cells to drugs. Using actinomycin D, a drug of

Mechanism of resistance to cisplatin in

Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53

✍ Faina Vikhanskaya; Luana Clerico; Monica Valenti; Maria S. Stanzione; Massimo Br 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 99 KB 👁 2 views

A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity a

Establishment of a human non-small cell

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib

✍ Fumiaki Koizumi; Tatsu Shimoyama; Fumiko Taguchi; Nagahiro Saijo; Kazuto Nishio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 672 KB

## Abstract The epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor gefitinib (Iressa®, ZD1839) has shown promising activity preclinically and clinically. Because comparative investigations of drug‐resistant sublines with their parental cells are useful approaches to identifying the m